These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30085899)

  • 1. Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study.
    Colombo D; Caltagirone C; Padovani A; Sorbi S; Spalletta G; Simoni L; Ori A; Zagni E
    J Womens Health (Larchmt); 2018 Nov; 27(11):1368-1377. PubMed ID: 30085899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
    Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
    Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.
    Servello A; Ettorre E; Cacciafesta M
    Panminerva Med; 2017 Sep; 59(3):275-277. PubMed ID: 28665099
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.
    Tsuno N; Mori T; Ishikawa I; Bando N; Park H; Matsumoto Y; Mori I; Tanaka M; Hirano T; Nakamura Y
    Geriatr Gerontol Int; 2019 Jul; 19(7):571-576. PubMed ID: 30864298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in presentation of behavioral and psychological symptoms in Alzheimer's disease in Taiwan.
    Hsieh SW; Chen CH; Huang LC; Chang YH; Yang YH
    Aging Ment Health; 2020 Aug; 24(8):1342-1347. PubMed ID: 30912669
    [No Abstract]   [Full Text] [Related]  

  • 8. Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.
    Spalletta G; Caltagirone C; Padovani A; Sorbi S; Attar M; Colombo D; Cravello L;
    PLoS One; 2014; 9(2):e89216. PubMed ID: 24586603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment.
    Fernández M; Gobartt AL; Balañá M;
    BMC Neurol; 2010 Sep; 10():87. PubMed ID: 20920205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
    Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
    PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
    Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
    Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep disturbances are key symptoms of very early stage Alzheimer disease with behavioral and psychological symptoms: a Japan multi-center cross-sectional study (J-BIRD).
    Kabeshita Y; Adachi H; Matsushita M; Kanemoto H; Sato S; Suzuki Y; Yoshiyama K; Shimomura T; Yoshida T; Shimizu H; Matsumoto T; Mori T; Kashibayashi T; Tanaka H; Hatada Y; Hashimoto M; Nishio Y; Komori K; Tanaka T; Yokoyama K; Tanimukai S; Ikeda M; Takeda M; Mori E; Kudo T; Kazui H
    Int J Geriatr Psychiatry; 2017 Feb; 32(2):222-230. PubMed ID: 27001907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.